Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Papillomavirus Infections 1Carcinoma in Situ 1

Interventions

pembrolizumab 70Cyclophosphamide 46Cisplatin 42Nivolumab 33Radiotherapy 30Paclitaxel 30Gemcitabine 30Carboplatin 28Docetaxel 26Dexamethasone 22atezolizumab 20Blood Specimen Collection 20Bevacizumab 19Rituximab 18Radiosurgery 18Fluorouracil 18fludarabine 17Magnetic Resonance Spectroscopy 17Leucovorin 17Lenalidomide 17Surveys and Questionnaires 16Oxaliplatin 16Doxorubicin 15Irinotecan 14Etoposide 14palbociclib 13Vincristine 13Radiotherapy, Intensity-Modulated 13Prednisone 13Letrozole 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Codeine × 90 days × Clear all
NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡